Literature DB >> 11738909

Laser in situ keratomileusis with a scanning excimer laser for the correction of low to moderate myopia with and without astigmatism.

G Balazsi1, M Mullie, L Lasswell, P A Lee, Y J Duh.   

Abstract

PURPOSE: To evaluate the safety and effectiveness of and patient satisfaction with laser in situ keratomileusis (LASIK) performed with a scanning excimer laser by experienced surgeons to correct low and moderate levels of myopia and astigmatism.
SETTING: Clinique Laservue, Montreal, Quebec, Canada.
METHODS: A consecutive series of 125 patients (236 eyes) with myopia of -0.5 to -7.0 diopters (D) and cylinder less than 2.5 D were enrolled in this single-center prospective clinical trial. The patients were treated with LASIK and followed for 6 months. The System-ALK Automated Corneal Shaper microkeratome (Bausch & Lomb Surgical) with a 180 microm thickness plate and the Technolas 217 excimer laser (Bausch & Lomb Surgical) with PlanoScan software for the stromal ablation were used in all procedures. Since this version of PlanoScan tended to undercorrect, a mean of 14.7% was added to the standard nomogram. Patient satisfaction was assessed by questionnaires administered preoperatively and 1 and 6 months postoperatively. Retreatments for enhancement were not performed during the 6-month follow-up.
RESULTS: Six months after LASIK (86.4% follow-up), the mean postoperative manifest spherical equivalent was +0.02 D +/- 0.64 (SD) compared with a preoperative mean of -4.01 +/- 1.59 D. The uncorrected visual acuity was 20/40 or better in 94.6% of eyes and 20/20 or better in 81.9%. A total of 91.2% were within +/-1.0 D of emmetropia and 73.0% were within +/-0.5 D. Only 2 eyes were overcorrected by >1.0 D. Of the eyes with astigmatic myopia, 86.8% were within +/-1.0 D of the intended cylinder correction (by vector analysis) and 73.0% were within +/-0.5 D. The refractions were generally stable after 1 month, and the change in refraction between postoperative examinations was within +/-0.5 D in 88.0% of eyes. A 1-line decrease in best spectacle-corrected visual acuity was seen in 11.3% of eyes, and no eye lost more than 1 line. An increase of 1 or 2 lines was seen in 45.1%. No intraoperative problems occurred, and the interface was clear in all eyes. At 6 months, most symptoms present significantly more frequently than preoperatively were "mild"; none were "marked" or "severe." A total of 90.5% of eyes were reported with marked to extreme improvement in the overall quality of vision, and 99.0% of patients said they would choose LASIK surgery again.
CONCLUSIONS: Mild to moderate myopia, with and without astigmatism, was corrected safely, effectively, and predictably with a high degree of patient satisfaction using LASIK with a scanning excimer laser and the System-ALK Automated Corneal Shaper.

Entities:  

Mesh:

Year:  2001        PMID: 11738909     DOI: 10.1016/s0886-3350(01)01017-3

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  Visual and non-visual factors associated with patient satisfaction and quality of life in LASIK.

Authors:  P Lazon de la Jara; D Erickson; P Erickson; F Stapleton
Journal:  Eye (Lond)       Date:  2011-07-01       Impact factor: 3.775

2.  Comparing aspheric ablation profile with standard corneal ablation for correction of myopia and myopic astigmatism, a contralateral eye study.

Authors:  Mohammad Ghoreishi; Afsaneh Naderi Beni; Zahra Naderi Beni; Alireza Zandi; Farzan Kianersi
Journal:  Lasers Med Sci       Date:  2017-10-23       Impact factor: 3.161

3.  Laser in situ keratomileusis for astigmatism ≤ 0.75 diopter combined with low myopia: a retrospective data analysis.

Authors:  Toam Katz; Andreas Frings; Stephan J Linke; Gisbert Richard; Vasyl Druchkiv; Johannes Steinberg
Journal:  BMC Ophthalmol       Date:  2014-01-06       Impact factor: 2.209

4.  Comparison of outcomes of conventional WaveLight(®) Allegretto Wave(®) and Technolas(®) excimer lasers in myopic laser in situ keratomileusis.

Authors:  Daphne Cy Han; Jean Chen; Hla Myint Htoon; Donald Th Tan; Jodhbir S Mehta
Journal:  Clin Ophthalmol       Date:  2012-07-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.